Impact of Dapagliflozin on cardiac remodeling in patients with chronic heart failure: DAPA-MODA study.
D A Pascual-FigalJ L ZamoranoM DomingoH MorillasJ NuñezM Cobo MarcosA Riquelme-PérezAlbert TeisE SantasC CaroJ M PinillaJ F Rodriguez-PalomaresD Dobarronull Restrepo-CórdobaJ R González-JuanateyA Bayés Genísnull nullDomingo Pascual FigalAlejandro Pérez RiquelmeCesar CaroÁlvaro Hernández VicenteAndrés Ramón MartínezMª Teresa Pérez MartínezJose A Noguera VelascoIría Cebreiros LópezDaniel SauraMª José Oliva SandovalJosefa González CarrilloMaría Dolores Espinosa GarcíaAntoni Bayes-GenísMar DomingoAlbert TeisHerminio MorillasAlfonso Valle MuñozEmilio Galcerá JornetJulia Seller MoyaEnrique SantasJulio NúñezRafael de la EspriellaMarta Cobo MarcosJose Manuel PinillaConcepción Cruzado ÁlvarezClara Jiménez RubioAinhoa Robles MezcuaJose F Rodríguez PalomaresJavier Limeres FreireAna B MéndezDavid DobarroMaría Melendo-ViuM Ángeles Restrepo-CordobaJosebe Goirigolzarri-ArtazaMarcos Ferrández-EscarabajalDavid García VegaJosé Seijas AmigoJose Ramón González JuanateyMartina Amiguet CominsPublished in: European journal of heart failure (2023)
Dapagliflozin administration in stable out-setting patients with chronic HF and optimized therapy results in global reverse remodeling of cardiac structure, including reductions in LA volumes and improvement in LV geometry and NT-proBNP concentrations. This article is protected by copyright. All rights reserved.